Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Cancer Biother Radiopharm. 2008 Aug;23(4):411–423. doi: 10.1089/cbr.2007.0450

Figure 3.

Figure 3

(A) Biodistribution of 111In-CHX-A″-DTPA hu3S193 multimer, and (B) 111In-CHX-A″-DTPA hu3S193 F(ab′)2 in normal tissues and tumors at 10 minutes and 2, 6, and at 24 hours postinjection. (C) Clearance and tumor localization of 111In-CHX-A″-DTPA hu3S193 multimer and (D) 111In-CHX-A″-DTPA hu3S193 F(ab″)2 in blood (■), MCF-7 tumor (▲), and control SW1222 tumor (▼). Data are expressed as the mean ± standard deviation of the %ID/g for respective groups of n = 5.